Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
IOVA.US
id: 1086
Iovance Biotherapeutics (IOVA) FDA Suspending Clinical Trial Case
- On December 27, 2023, Iovance (IOVA) announced that, on December 22, 2023, the FDA had placed a clinical hold on a Company’s clinical trial.
- On it, $OIVA fell 18,67%, losing $424M+ of shareholder value.
- Investors may have grounds to suspect Iovance of a failed clinical trial, which led to their losses.
On December 27, 2023, Iovance announced that, on December 22, 2023, U.S. FDA had placed a clinical hold on the Company’s trial of lead product candidate for the treatment of metastatic non-small cell lung cancer.
Iovance advised that the FDA’s decision to place the clinical hold was in response to a recently reported Grade 5 (fatal) serious adverse event.
On this news, $IOVA fell 18,67% and lost over $424 million of its market capitalization, seriously damaging shareholders.
Considering all the information, investors might have grounds to suspect Iovance of facing a significant delay in bringing a product to market, which led to their losses.
The case is already under investigation by at least one of the reputable law firms.
Case Status
Attorney Investigation
Alleged Offence
Misleading Statements,
Failure to Disclose,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
12/27/2023